Quantitative analysis of 18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′-methyl-phenyl) nortropane binding to the dopamine transporter in Parkinson …

P Fazio, P Svenningsson, A Forsberg… - Journal of Nuclear …, 2015 - jnm.snmjournals.org
18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′-methyl-phenyl) nortropane
(18F-FE-PE2I) is a recently developed radioligand for the in vivo quantification of the …

A randomized placebo controlled trial demonstrates the effect of dl-methylephedrine on brain functions is weaker than that of pseudoephedrine

T Sakayori, Y Ikeda, R Arakawa, T Nogami… - Scientific Reports, 2024 - nature.com
Intellectual drug do** in athletics by using stimulants that affect central nervous system
functions has been diversified. Stimulants are regulated by the World Anti-Do** Agency …

Dynamic changes in striatal mGluR1 but not mGluR5 during pathological progression of Parkinson's disease in human alpha-synuclein A53T transgenic rats: a multi …

T Yamasaki, M Fu**aga, K Kawamura… - Journal of …, 2016 - jneurosci.org
Parkinson's disease (PD) is a prevalent degenerative disorder affecting the CNS that is
primarily characterized by resting tremor and movement deficits. Group I metabotropic …

[HTML][HTML] Longitudinal DAT changes measured with [18F] FE-PE2I PET in patients with Parkinson's disease; a validation study

VS Kerstens, P Fazio, M Sundgren, J Brumberg… - NeuroImage: Clinical, 2023 - Elsevier
Abstract Background Dopamine transporter (DAT) PET provides higher resolution than DAT
SPECT and opportunity for integrated imaging with MRI. The radioligand [18 F] FE-PE2I is …

[18F]FE-PE2I PET is a feasible alternative to [123I]FP-CIT SPECT for dopamine transporter imaging in clinically uncertain parkinsonism

L Marner, K Korsholm, L Anderberg, MN Lonsdale… - EJNMMI research, 2022 - Springer
Background Dopamine transporter (DAT) imaging of striatum is clinically used in Parkinson's
disease (PD) and neurodegenerative parkinsonian syndromes (PS) especially in the early …

Reliability of dopamine transporter PET measurements with [18F]FE-PE2I in patients with Parkinson's disease

VS Kerstens, P Fazio, M Sundgren, GJ Matheson… - EJNMMI research, 2020 - Springer
Background Reliable quantification of dopamine transporter (DAT), a biomarker for
Parkinson's disease (PD), is essential for diagnostic purposes as well as for evaluation of …

Principal component analysis of multimodal neuromelanin MRI and dopamine transporter PET data provides a specific metric for the nigral dopaminergic neuronal …

H Kawaguchi, H Shimada, F Kodaka, M Suzuki… - PLoS …, 2016 - journals.plos.org
The loss of dopaminergic (DA) neurons in the substantia nigra (SN) is a major
pathophysiological feature of patients with Parkinson's disease (PD). As nigral DA neurons …

Ventral striatal dopamine transporter availability is associated with lower trait motor impulsivity in healthy adults

CT Smith, MD San Juan, LC Dang, DT Katz… - Translational …, 2018 - nature.com
Impulsivity is a transdiagnostic feature of a range of externalizing psychiatric disorders.
Preclinical work links reduced ventral striatal dopamine transporter (DAT) availability with …

Optimal acquisition time window and simplified quantification of dopamine transporter availability using 18F-FE-PE2I in healthy controls and Parkinson disease …

I Sonni, P Fazio, M Schain, C Halldin… - Journal of Nuclear …, 2016 - jnm.snmjournals.org
18F-(E)-N-(3-iodoprop-2-enyl)-2β-carbofluoroethoxy-3β-(4′ methylphenyl) nortropane (18F-
FE-PE2I) is a newly developed dopamine transporter (DAT) PET radioligand. Full …

[HTML][HTML] Differential associations of dopamine synthesis capacity with the dopamine transporter and D2 receptor availability as assessed by PET in the living human …

Y Yamamoto, K Takahata, M Kubota, H Takano… - Neuroimage, 2021 - Elsevier
Background: The dopamine (DA) neurotransmission has been implicated in fundamental
brain functions, exemplified by movement controls, reward-seeking, motivation, and …